Ulodesine succinate anhydrous
Product Specifications
CAS Number
1246200-39-4
Bioactivity
Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC (50) ) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.
Smiles
OC(CCC(O)=O)=O.O=C(N=CN1)C2=C1C(CN3C[C@@H]([C@H](C3)O)CO)=CN2.O=C(N=CN4)C5=C4C(CN6C[C@@H]([C@H](C6)O)CO)=CN5
Molecular Formula
C12H16N4O3 1/2C4H6O4
Molecular Weight
323.325
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Product Datasheet
https://www.targetmol.com/attachment/DataSheet/293082588975726683/T202983
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RC227326L4V 200 µL
C6orf52 (NM_001145020) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details 
